The School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo has received grants to continue HIV and AIDS research through at least 2020.
The National Institutes of Health has awarded the University at Buffalo’s AIDS Clinical Trials Group (ACTG) Pharmacology Specialty Laboratory (PSL) three grants totaling $3.85 million. The PSL is one of six labs globally, according to the
UB Reporter.
“The UB laboratory receives funding toward developmental pharmacology initiatives in HIV clinical pharmacology and hepatitis C virus drug development,” Gene D. Morse, a professor of pharmacy practice and principal investigator on the grants, told the UB Reporter. “As well as continued coordination of a national pharmacoinformatics and drug interactions database project.”
Initially funded in 1987, the UB program has received ongoing funding to collaborate with researchers and pharmaceutical companies from around the world and U.S. to find interdisciplinary approaches to drug development, according to
Buffalo Business First.
“We hope to develop approaches that characterize drug distribution into different body tissues and fluids and combine that with analysis of gastrointestinal and liver drug metabolism,” Morse told Buffalo Business First.
The University at Buffalo aims to educate pharmacy students to increase their knowledge of HIV treatment. The increasing life span of HIV positive patients has brought unique challenges to the pharmaceutical world and pharmaceutical professionals, according to the
ePharmacotherapy Network on the UB official website.
UB School of Pharmacy and Pharmaceutical Sciences HIV Online Educational Offerings wants students and pharmacists to feel more comfortable with their knowledge of “the basic pathophysiology of HIV and pharmacology of antiretrovirals” by incorporating the practice into the education students receive, according to the website.
